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Abstract
Background: Geographic variation in traditional cardiovascular disease (CVD) risk factors has been observed among women
in the US. It is not known whether state-level variation in cardiovascular inflammation exists or could be explained by
traditional clinical risk factors and behavioral lifestyle factors.
Methods and Results: We used multilevel linear regression to estimate state-level variation in inflammatory biomarker
patterns adjusted for clinical and lifestyle characteristics among 26,029 women free of CVD. Participants derived from the
Women’s Health Study, a national cohort of healthy middle-aged and older women. Inflammatory biomarker patterns
(plasma levels of high-sensitivity C-reactive protein (hsCRP), soluble intercellular adhesion molecule-1 (sICAM-1), and
fibrinogen) were compared to state-level patterns of traditional CVD risk factors and global risk scores. We found that all
three inflammatory biomarkers exhibited significant state-level variation including hsCRP (lowest vs. highest state median
1.3 mg/L vs. 2.7 mg/L, unadjusted random effect estimate 1
st to 99
th percentile range for log hsCRP 0.52, p,.001), sICAM-1
(325 ng/ml vs. 366ng/ml, unadjusted random effect estimate 1
st to 99
th percentile range 0.44, p,.001), and fibrinogen
(322 mg/dL vs. 367 mg/dL, unadjusted random effect estimate 1
st to 99
th percentile range 0.41, p=.001). Neither
demographic, clinical or lifestyle characteristics explained away state-level effects in biomarker patterns. Southern and
Appalachian states (Arkansas, West Virginia) had the highest inflammatory biomarker values. Regional geographic patterns
of traditional CVD risk factors and risk scores did not completely overlap with biomarkers of inflammation.
Conclusions: There is state-level geographic variation in inflammatory biomarkers among otherwise healthy women that
cannot be completely attributed to traditional clinical risk factors or lifestyle characteristics. Future research should aim to
identify additional factors that may explain geographic variation in biomarkers of inflammation among healthy women.
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Introduction
Inflammation is a major determinant of atherothrombotic
cardiovascular disease (CVD) events [1]. Elevated plasma levels of
several inflammatory biomarkers including high sensitivity C-
reactive protein (hsCRP), soluble intercellular adhesion molecule
type 1 (sICAM-1), and fibrinogen have been consistently found to
predict future CVD events – including strokes and heart attacks –
in healthy populations, particularly in women [1–5]. The clinical
and public health importance of these inflammatory biomarkers
is increasingly recognized [6–8]. In a recent comprehensive
meta-analysis of 54 prospective cohort studies, the magnitude of
risk associated with a one standard deviation increase in hsCRP
was at least as large as that associated with a similar change in
blood pressure or cholesterol [9].
Despite these data, factors that contribute to population-level
differences in cardiovascular inflammation have not been fully
explored. From a public health perspective, studying population-
level differences in inflammation in healthy populations may
be useful to suggest novel prevention strategies that influence
atherogenic processes early in the course of CVD. Recently,
regional geographic differences in traditional CVD risk factors
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27468have been described [10–13]. To date, however, comparable data
evaluating geographic patterns in inflammatory biomarkers have
not been reported. In particular, it is not known whether there is
geographic variation in inflammation in relatively lower-risk,
healthy populations who have yet to develop CVD. Moreover, it is
not clear whether any geographic variation in inflammation would
simply reflect the presence of known clinical and behavioral CVD
risk factors.
To address these issues, we evaluated state-level profiles of
hsCRP, sICAM-1, and fibrinogen in a large-scale cohort of healthy
women in the United States, in which the prevalence of traditional
CVD risk factors is low. Using multilevel linear regression analysis
as well as mapping techniques, we further sought evidence as to (a)
whether any observed geographic patterns of inflammation were
independent of traditional CVD risk factors (cholesterol, body mass
index (BMI), systolic blood pressure, diabetes) and behavioral
factors (smoking, exercise, calorie consumption) in these healthy
women; and (b) whether inflammatory biomarker geographic
patterns share overlap with related CVD risk factors (cholesterol,
BMI) and global CVD risk scores (Framingham Point Score,
Reynolds Risk Score) in these otherwise healthy women.
Methods
Study Participants, Laboratory Evaluation and Survey
Data
Written informed consent was obtained from participants for
inclusion in the study cohort. Consent procedures and other study
procedures for these analyses were reviewed and approved by the
Institutional Review Board of Partners HealthCare (Boston, MA).
The study population derived from the 39,876 participants of
the Women’s Health Study (WHS), a nation-wide study of female
health professionals, aged 38 and older, residing in the United
States [14]. Participants were free from CVD and cancer at
baseline between 1993 and 1996. The WHS cohort included
28,296 women who provided blood samples at baseline. WHS
participants eligible for inclusion in this analysis (n=26,029) had
complete baseline data on blood-derived biomarkers and clinical
Table 1. Selected Demographic, Lifestyle, and Clinical Characteristics of Women’s Health Study Participants: With State-Level
Comparisons.
All Participants U.S. State-Level Percentile Ranges
N=26,029 N=51
All States 1
st 25
th 50
th 75
th 99
th
Demographic
Age, median (IQR), y 53 (49- 59) 51 52 53 53 54
NH-White{ 24,716 (95.0) 84% 93% 96% 98% 100%
Non-White 1,313 (5.0) 16% 7% 4% 2% 0%
NH-Black 444 (1.7) - - - - -
Hispanic 225 (0.9) - - - - -
Asian Pacific 343 (1.3) - - - - -
Other/Unknown 301 (1.1) - - - - -
Lifestyle
Current smoker 2,983 (11) 4% 9% 11% 13% 17%
Exercise rarely/never 9,642 (37) 16% 33% 38% 40% 52%
Median Daily Caloric intake, 1676 (1350- 2052) 1354 1646 1688 1721 1946
median (IQR), kCal
Clinical
hsCRP median (IQR), mg/L 2.0 (0.80- 4.3) 0.9 1.8 2.1 2.2 2.7
sICAM-1 median (IQR), ng/mL 342 (301- 394) 320 338 344 349 366
Fibrinogen median (IQR), mg/dL 351 (307- 403) 322 345 351 356 385
Total Cholesterol, median (IQR), mg/dL 208 (184- 235) 197 206 208 210 218
Cholesterol:HDL-C Ratio, median (IQR) 4.0 (3.2- 4.9) 3.5 3.9 4.0 4.1 4.3
Framingham Point Score, median (IQR) 12 (9- 15) 11 12 12 12 13
Reynolds Risk Score, median (IQR) 1.5 (0.74- 3.2) 0.9 1.3 1.4 1.6 2.0
BMI, median (IQR), kg/m2 24.9 (22.5- 28.3) 23.3 24.6 24.9 25.1 25.8
Systolic blood pressure category, 125 (115- 135) 115 125 125 125 125
median (IQR), mmHg
Percent with diabetes 754 (2.9) 0% 2.4% 2.8% 3.5% 4.7%
Source: Women’s Health Study (WHS). Figures are No.(%) unless otherwise noted. Abbreviations: NH (Non-Hispanic ethnicity); hsCRP (high-sensitivity C-reactive protein);
sICAM-1 (soluble intercellular adhesion molecule); HDL-C (high-density lipoprotein cholesterol); BMI (body mass index); IQR (inter-quartile range). State-level percentiles
based on ranges of 50 US States plus the District of Columbia. ‘‘Asian’’ includes Asian/Pacific Islander; ‘‘Other/Unknown,’’ includes American Indian/Native American/
Alaska Native.
doi:10.1371/journal.pone.0027468.t001
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clinical and lifestyle characteristics.
Blood-derived measures included hsCRP, sICAM-1, fibrinogen,
total cholesterol, high density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), and hemoglobin A1c
(HbA1c). The laboratory facility that assayed the blood-derived
measures was certified by the National Heart, Lung, and Blood
Institute/Centers for Disease Control and Prevention Lipid Stan-
dardization Program.
Self-reported data assessed participant age, race/ethnicity,
height, weight, blood pressure, diabetes, exercise frequency,
smoking status, and caloric intake at baseline at the time of the
blood draw. The classification of diabetes was further refined using
HbA1c of greater or equal to 6.5% to reclassify those who reported
not having diabetes as being diabetic, consistent with 2010
American Diabetes Association guidelines. Two global risk scores
that predict future CVD events, the Framingham Point Score and
the Reynolds Risk Score were calculated with laboratory and
clinical survey data (see appendix) [15,16].
Statistical Analysis and Geographic Mapping
We report descriptive statistics at the individual level, and
percentile ranges at the state-level for demographic characteristics,
inflammatory biomarkers, clinical and behavioral risk factors, and
global CVD risk score values.
Sequential multilevel regression models were estimated for each
outcome measure: three biomarkers (hsCRP, sICAM-1, fibrinogen,
assessed separately), two cholesterol measures (total cholesterol, and
total cholesterol:HDL-C ratio), BMI, and each global CVD risk
score (Framingham Point Score, and Reynolds Risk Score). A
‘‘null’’ model without individual-level covariates was estimated to
quantify the total variance at the state level for each outcome
measure. An age-adjusted model was estimated to quantify the
state-level biomarker variance not accounted for by differences in
age distributions within states. A third model with demographic and
clinical variables (age, race/ethnicity, diabetes, obesity/overweight,
systolic blood pressure, cholesterol) was estimated to quantify the
inflammatory biomarker and cholesterol variation between states
that was not explained by clinical characteristics of the participants
within states. Models with cholesterol measures as the outcome
variables did not include cholesterol as covariates. A fourth fully-
adjusted set of models was constructed for each of the three
inflammatory biomarkers to add the lifestyle factors as covariates
(smoking, exercise level, average daily caloric intake). A similar
fourth set of models was constructed for cholesterol as outcome
measures, also adjusting for clinical and lifestyle factors (and
excluding cholesterol as covariates). The measures for BMI (as a
continuous variable), the Framingham Point Score and Reynolds
Risk Score were not adjusted for covariates. Measurements for
hsCRP and BMI were log-transformed prior to incorporation in
multivariable models due to skewed values.
Standardized random effect estimates and intraclass correlations
at the state level were used to quantify the variance between states
compared to variance within states for each of the three inflam-
matory biomarkers (hsCRP, sICAM-1, fibrinogen), measures of
cholesterol (total cholesterol, total cholesterol:HDL-C ratio), BMI
and global risk scores. We estimated state-level random effect
coefficients and intraclass correlations using multilevel linear
regression in the MIXED procedure in SAS (SAS Institute Inc.,
Cary, NC, USA).
In multilevel regression analysis, the random effects variance
(s
2
State) represents the variance in an outcome variable, in this
Figure 1. State-level Variation in Cardiovascular Biomarkers of Inflammation in the Women’s Health Study. Source: Women’s Health
Study Participants. Abbreviations: Q1: Lowest quintile of inflammation; Q5: Highest quintile of inflammation. Fully-adjusted models include: age, race/
ethnicity, obese/overweight status, systolic blood pressure, diabetes status, HDL-C, LDL-C, smoking, exercise, caloric intake.
doi:10.1371/journal.pone.0027468.g001
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to which individuals are classified, in this case the state of residence
of the participant. State-level standardized random effect estimates
are presented as the range between the 1
st and 99
th percentile of
the random effects distribution. Based on the normal assumption
for the state-specific random effects, this range corresponds to:
6|
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2State
p
For all multilevel regression models, restricted maximum
likelihood estimation (REML) was used to calculate variance
components. The statistical significance of the random effects
variance component, specifically, the test of the null hypothesis that
there is no state-level variation in each measure of inflammation,
cholesterol, BMI or global risk score, was assessed by the Wald Z-
test in the MIXED procedure in SAS.
Estimates of the state-specific random effects (residuals) for each
biomarker, cholesterol measure and risk score outcome variable
were mapped within ArcGIS software version 9.3 (ESRI,
Redlands, CA) to visualize qualitative differences among the fifty
states and the District of Columbia (Washington D.C.) [17]. Five-
level color ramps were used to divide the state-specific residuals
into quintiles. The map of BMI was presented as state-level
median values divided in normal weight (# 24.9 kg/m2) and
overweight categories (25.0 kg/m2 and over) to facilitate compar-
ison with published maps. Last, multilevel regression models were
repeated using the ten Federal Standard Regions as the random
classification variable to test for the presence of broad regional
patterns in the data.
Table 2. State-Level Variation in Cardiovascular Inflammatory Biomarkers, Risk Factors, and Clinical Risk Scores.
State-level Random Effects Estimates (P Value)
Outcome Variable Value Model I Model II Model III Model IV
hsCRP(Log)
Estimate
* (P value) 0.52 (,.001) 0.50 (,.001) 0.47 (,.001) 0.46 (,.001)
ICC (%) 0.76 0.71 0.78 0.76
sICAM-1
Estimate
* (P value) 0.44 (,.001) 0.42 (.001) 0.31 (.01) 0.26 (.01)
ICC (%) 0.55 0.50 0.30 0.23
Fibrinogen
Estimate
* (P value) 0.41 (.001) 0.41 (.001) 0.30 (0.005) 0.26 (.01)
ICC (%) 0.47 0.48 0.29 0.22
Total Cholesterol
{
Estimate
* (P value) 0.43 (,.001) 0.44 (,.001) 0.45 (.001)
{ 0.44 (.001)
{
ICC (%) 0.52 0.55 0.58 0.56
Total Cholesterol: HDL-C Ratio
{
Estimate
* (P value) 0.47 (,.001) 0.46 (,.001) 0.40 (,.001)
{ 0.34 (.001)
{
ICC (%) 0.61 0.60 0.52 0.40
BMI(Log)
Estimate
* (P value) 0.35 (.001) - - -
ICC (%) 0.35
Framingham Point Score
Estimate
* (P value) 0.40 (,.001) - - -
ICC (%) 0.45
Reynolds Risk Score
Estimate
* (P value) 0.37 (.001) - - -
ICC (%) 0.38
Source: Women’s Health Study. Abbreviations: hsCRP(Log) (natural log of high sensitivity C-reactive protein);
sICAM-1 (soluble intercelluar adhesion molecule); HDL-C (high-density lipoprotein cholesterol); LDL-C (low-density lipoprotein cholesterol); BMI(Log) (natural log of
body mass index); ICC (intra-class correlation).
Multilevel linear regression random effect estimates and intraclass correlations estimate the presence non-zero variance in inflammatory biomarkers, cholesterol, BMI
(log), or risk scores at the state level. P value # 0.05 rejects null hypothesis of zero variance among states.
*Estimates presented as 1
st to 99
th percentile range.
{Models of cholesterol as the outcome variable do not control for cholesterol measures within the model. Models for BMI, Framingham and Reynolds risk scores are not
adjusted for covariates.
Model I. Unadjusted.
Model II. Age-adjusted.
Model III. Adjusted for age, race, obesity/overweight, diabetes, systolic blood pressure, HDL-C
{, LDL-C
{
Model IV. Adjusted for age, race, obesity/overweight, diabetes, systolic blood pressure, HDL-C
{, LDL-C
{, exercise,
smoking status, daily caloric intake.
doi:10.1371/journal.pone.0027468.t002
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Cary, NC). Maps were created in ArcGIS ArcMAP software
version 9.3 (ESRI, Redlands, CA).
Results
The WHS cohort is geographically diverse. All states except
Hawaii (n=8) and Washington D.C. (n=25) were well-sampled.
In all other states there were more than fifty WHS participants per
state, ranging from n=58 WHS participants in Alaska to
n=2,639 WHS participants in California.
Table 1 presents biomarker levels, clinical and lifestyle data on
all study participants, as well as state-level distributions of these
characteristics, from the 1
st to the 99
th percentile. Among states
that were well-sampled, the full distribution of median hsCRP
values had a clinically significant range of moderately-low risk
values (1.3 to 1.6 mg/L in Iowa, Massachusetts, and New York) to
moderately-higher risk values (from 2.5 to 2.7 mg/L in Texas,
Louisiana, Alabama, Arkansas and West Virginia). The lowest
state-level values for both sICAM-1 (325 ng/ml) and fibrinogen
(322 mg/dL) were seen in Iowa. The highest state-level values
were seen in Arkansas for both sICAM-1 (366 ng/ml) and
Figure 2. State-level Variation in Cholesterol in the Women’s Health Study. Source: Women’s Health Study Participants. Abbreviations: Q1:
Lowest quintile of risk; Q5: Highest quintile of risk. Fully-adjusted models include: age, race/ethnicity, obese/overweight status, systolic blood
pressure, diabetes status, smoking, exercise, caloric intake.
doi:10.1371/journal.pone.0027468.g002
Figure 3. State-level Variation in Cardiovascular Risk Scores and State Median BMI in the Women’s Health Study. Source: Women’s
Health Study Participants. Abbreviations: Q1: Lowest quintile of risk; Q5: Highest quintile of risk. Models not adjusted for covariates.
doi:10.1371/journal.pone.0027468.g003
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listed in Table S1.
Among the traditional risk factors, median total cholesterol
values were clinically low risk to borderline-elevated, lowest in
Iowa and Utah (197 mg/dL) and highest in Wyoming (218 mg/
dL) and Arkansas (215 mg/dL). For states that were well-sampled,
median values for the total cholesterol:HDL-C ratio were
moderately-low risk values from 3.7 (California) to 4.3 (West
Virginia). Among half of states (n=25), median BMI values were
in the overweight range (24.95 – 25.8 kg/m
2) highest in Utah and
West Virginia. No state had a median BMI value in the obese
range among WHS participants. Framingham Point Score values
ranged from a median value of 11 (including Delaware and Iowa),
corresponding to 1% 10-year risk of CVD events, to 13 (Arkansas
and Pennsylvania), corresponding to a 2% 10-year risk of CVD
events. Similarly, Reynolds Risk Score median values ranged from
a 1.2% 10-year risk of CVD events (Vermont, Maryland, Iowa,
Oregon, Nebraska), to 2.0% 10-year risk (Arkansas).
Figure 1 shows state-level patterns in biomarkers of inflamma-
tion adjusted for (a) age, and (b) for the clinical and lifestyle
characteristics of women living in the state. State-level random
effect estimates quantifying the biomarker patterns are listed in
Table 2. Unadjusted state-level intraclass correlations ranged
between 0.35% and 0.76%. Statistically significant state-level
variation was seen for each of the three biomarkers before and
after adjustment for covariates. State-level patterns in hsCRP were
only marginally affected by adjustment for clinical and lifestyle
characteristics of WHS participants. For hsCRP, the unadjusted
state-level variance was 0.52 (p,.001). Adjustment for clinical and
lifestyle characteristics decreased state-level variation in hsCRP by
12%. The presence of clinical factors (overweight and obesity,
systolic blood pressure, diabetes, HDL-C, LDL-C) appeared to
explain more state-level variation in hsCRP than lifestyle factors
(exercise, smoking status, daily caloric intake), though statistically
significant state-level variation in hsCRP was still apparent after
full adjustment for the above covariates (0.46, p,.001). More of
the state-level variance in sICAM-1 and fibrinogen was explained
by clinical and lifestyle characteristics than was seen for hsCRP. In
particular, state-level variance in both sICAM-1 and fibrinogen
were more sensitive to women’s lifestyle characteristics than seen
in hsCRP. The linear associations between biomarkers of
inflammation and study participants’ clinical and lifestyle charac-
teristics as estimated in multilevel models are presented in Tables
S2, S3 and S4.
Figure 2 shows comparable state-level patterns of geographic
variation in total cholesterol, and the total cholesterol:HDL-C
ratio. The total cholesterol:HDL-C ratio can be interpreted as the
proportion of the cholesterol profile that is made up of HDL-C or
‘‘good’’ cholesterol. State-level variance in total cholesterol was not
explained by individual-level clinical and lifestyle characteristics
(Table 2). In contrast, state-level variance in the total cholester-
ol:HDL-C ratio was reduced by 28% after full adjustment for
clinical and lifestyle covariates. Figure 3 displays state-level median
BMI, and state-level variation in the Framingham Point Score,
and the Reynolds Risk Score. State-level variations in BMI, the
Framingham Point Score, and Reynolds Risk Score were
statistically significant as shown in Table 2. Full size figures of
biomarker and risk score maps are available as online supplements
(Figures S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13).
Statistically significant broad regional patterns exist for all
biomarkers and clinical risk factors (Table 3). Almost all indicators
identified states in the southeastern and Appalachian Standard
Federal Regions IV and VI as areas of highest risk. After
adjustment for covariates, regional patterns for hsCRP and
sICAM-1 were similar; highest levels of inflammation were seen
in Regions IV and VI. Regions IV and VI and mid-Atlantic
Table 3. Standard Federal Regional-level Variation in Cardiovascular Inflammation, Cholesterol, BMI and Cardiovascular Risk Scores.
Random effects
Estimate
1
Intraclass
correlation (%) P Value Highest risk Lowest risk
hsCRP(Log)
* 0.49 0.85 0.02 Region IV, VI Region I, II
sICAM-1
* 0.21 0.15 0.05 Region IV, VI Region II
Fibrinogen
* 0.30 0.31 0.04 Region II, IV, VI Region VIII, IX
Cholesterol
{ 0.26 0.19 0.05 Region IX Region VIII, X
Cholesterol:HDL-C ratio
{ 0.27 0.25 0.04 Region IV, VI Region IX, X
BMI(Log)
{ 0.32 0.28 0.03 Region V, VII Region IX
Framingham Point Score
{ 0.30 0.26 0.04 Region IV, V, VI Region VIII, X
Reynolds Risk Score
{ 0.25 0.18 0.04 Region IV, V, VI Region II, VII, VIII
Source: Women’s Health Study.
*Biomarker models adjust for age, race, obesity/overweight, diabetes, systolic blood pressure, HDL-C, LDL-C, smoking, exercise, daily caloric intake.
{Models of total cholesterol and cholesterol:HDL-C ratio adjust for age, race, obesity/overweight, diabetes, systolic blood pressure, smoking, exercise, daily caloric intake.
{BMI, Framingham Point Score and Reynolds Risk Score do not include covariates.
1Estimates presented as 1
st to 99
th percentile range.
U.S. Standard Federal Regions:
Region I: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont.
Region II: New Jersey, New York.
Region III: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia.
Region IV: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee.
Region V: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin.
Region VI: Arkansas, Louisiana, New Mexico, Oklahoma, Texas.
Region VII: Iowa, Kansas, Missouri, Nebraska.
Region VIII: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming.
Region IX: Arizona, California, Hawaii, Nevada.
Region X: Alaska, Idaho, Oregon, Washington.
doi:10.1371/journal.pone.0027468.t003
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fibrinogen. Similar to hsCRP, sICAM-1 and fibrinogen, the total
cholesterol to HDL-C ratio, and the Framingham and Reynolds
Risk Scores identified Regions IV and VI as higher risk areas.
Both global CVD risk scores also identified the mid-western
Region V as an area of higher risk for future CVD events.
Regional inflammatory biomarker patterns differed from patterns
of BMI and total cholesterol without adjustment for HDL-C.
Region IX was identified as having the highest total cholesterol
values. BMI was highest in Regions V and VII. The areas of
lowest risk differed for each marker and risk factor, and most
commonly included Region II (hsCRP, sICAM-1 and Reynolds
Risk Score), Region VIII (fibrinogen, total cholesterol, Framing-
ham Point Score, and Reynolds Risk Score), Region IX
(fibrinogen, total cholesterol to HDL-C ratio, and BMI), and
Region X (total cholesterol, total cholesterol to HDL-C ratio, and
Framingham Point Score).
Discussion
Our analysis of 26,029 healthy women across the United
States found significant state to state variation in inflammation,
as measured by hsCRP, sICAM-1 and fibrinogen. We found
that the three biomarkers of inflammation identified similar
patterns of variability. Iowa was most consistently identified as
having the lowest median level of inflammation among healthy
women. States in the southeast and Appalachia, namely,
Arkansas and West Virginia, were most likely to have elevated
levels of inflammation. Notably, the range of state-level
variation we observed was clinically relevant. For hsCRP in
particular, state-level median values ranged from lower risk
values (1.3 mg/L in Iowa) to moderately-higher risk values
(2.7 mg/L in West Virginia). The southeast was identified as the
area of highest risk by each biomarker of inflammation, global
risk score, and the total cholesterol:HDL-C ratio. Moreover,
none of the clinical and lifestyle measures of overweight and
obesity, diabetes, systolic blood pressure, HDL-C, LDL-C,
smoking status, exercise patterns, or caloric intake fully
accounted for the state-level variation in biomarkers we
observed. More variability in sICAM-1 and fibrinogen was
accounted for by clinical and lifestyle factors than was seen for
hsCRP, though state-level patterns in all three biomarkers were
still apparent after adjustment for covariates.
Our data are consistent with findings in women from the
Reasons for Geographic and Racial Differences in Stroke
(REGARDS) study that found elevated hsCRP levels in the
‘‘stroke belt’’ region of the US (Alabama, Arkansas, Georgia,
Louisiana, Mississippi, North Carolina, South Carolina, and
Tennessee) [18]. Women in the REGARDS study who resided
in the stroke-belt region had 20% higher odds of an elevated
hsCRP of . 3 mg/L than women in the non-stroke belt regions;
this risk was independent of race/ethnicity, smoking status,
cholesterol status, overweight/obesity, blood pressure or the
presence of diabetes. Similarly, El Saed et al. found geographic
variability in stroke incidence in the Cardiovascular Health Study
[19]. As in our data, these differences in stroke incidence between
high and low risk geographies in the US were not explained by
differences in traditional CVD risk factors or medication use [20].
Our maps show a geographic pattern of inflammation that is
generally consistent with CVD mortality maps from the Centers of
Disease Control and Prevention (CDC) that show the southeastern
US as an area of high CVD mortality risk among women. Our
fibrinogen map appeared to match a west to east gradient in risk,
consistent with the known geography of CVD mortality.
The causal patterns underlying these regional effects are
uncertain. One potential cause is suggested in epidemiologic data
that demonstrate an environmental effect of particulate matter
exposure and elevated levels of fibrinogen and hsCRP in select
populations [21]. In other studies, populations in rural and
impoverished areas have been found to be at higher risk of
mortality than more urban, wealthy areas [22]. Our results suggest
the need for additional studies that tease out the effects of state-
level characteristics or contextual factors that may be associated
with geographically distributed risk for elevated inflammation.
Limitations of our study merit attention. One limitation is that
WHS participants are chiefly healthy, non-obese, of white non-
Hispanic race/ethnicity, and are health care professionals. Thus,
while internally valid, studies of other demographic groups are
needed prior to generalizing these data. These characteristics of the
WHS likely truncate and therefore under-estimate variability that
may exist among states that are more diverse than the WHS
population. However, the strength of examining geographic variation
in this healthy cohort is its applicability to primary prevention. Our
data highlight the extent to whichinflammation varies geographically
amongwomenpriortothe development ofclinicallyapparentCVD.
Inflammation is known to correlate with future risk of heart disease
among women, and biomarkers of inflammation improve risk
prediction for future CVD events [23]. Our study suggests the need
to understand population-level contributors to geographic patterns
intheearly developmentofCVD amongwomen,above and beyond
differences in the prevalence of known traditional risk factors.
Another limitation, ourstudy is cross-sectional and onlymeasures
inflammatory markers at one point in time during middle and older
age. With our study design, we cannot draw causal associations
between early life state of residence and inflammation among
individual women. An emerging literature suggests that those who
have lived in the southeastern US in childhood or adolescence have
an elevated risk for an incident CVD event, even if they had
subsequently left these regions [24]. In the WHS cohort, elevated
inflammation in women measured at older ages is known to
correlate with subsequent CVD events [2]. Thus, the extent to
which geographic exposures are correlated with risk of elevated
inflammation, population-health prevention efforts should address
these exposures across the life-course.
In summary, our study contributes to the literature on popula-
tionhealth by demonstrating geographicvariability in inflammation
amonghealthy women. Even amongotherwise healthy,chieflynon-
Hispanic white female health professionals, we found that those
living in southern and Appalachian states had high levels of
inflammation compared to women in other geographies. The geo-
graphic variation in inflammation we observed was in excess of
traditional clinical risk factors and lifestyle factors – a pattern that
has been observed previously in stroke outcomes [25]. Our findings
suggest a need for additional research to understand why there is
geographic variation in risk in these early biomarkers of ather-
osclerosis to inform primary prevention strategies. Importantly,
further research should find novel population-based strategies to
address the increased risk observed in the southern and Appala-
chian US, in ways that complement the control of traditional risk
factors.
Supporting Information
Figure S1 State-level Variation in Age-Adjusted C-reac-
tive Protein (CRP) in the Women’s Health Study. Source:
Women’s Health Study Participants. Abbreviations: Q1: Lowest
quintile of inflammation; Q5: Highest quintile of inflammation.
(TIF)
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1 in the Women’s Health Study. Source: Women’s Health
Study Participants. Abbreviations: Q1: Lowest quintile of inflam-
mation; Q5: Highest quintile of inflammation.
(TIF)
Figure S3 State-level Variation in Age-Adjusted Fibrin-
ogen in the Women’s Health Study. Source: Women’s
Health Study Participants. Abbreviations: Q1: Lowest quintile of
inflammation; Q5: Highest quintile of inflammation.
(TIF)
Figure S4 State-level Variation in Fully-Adjusted C-
reactive Protein (CRP) in the Women’s Health Study.
Source: Women’s Health Study Participants. Abbreviations: Q1:
Lowest quintile of inflammation; Q5: Highest quintile of
inflammation. Fully-adjusted models include: age, race/ethnicity,
obese/overweight status, systolic blood pressure, diabetes status,
HDL-C, LDL-C, smoking, exercise, caloric intake.
(TIF)
Figure S5 State-level Variation in Fully-Adjusted sI-
CAM-1 in the Women’s Health Study. Source: Women’s
Health Study Participants. Abbreviations: Q1: Lowest quintile of
inflammation; Q5: Highest quintile of inflammation. Fully-
adjusted models include: age, race/ethnicity, obese/overweight
status, systolic blood pressure, diabetes status, HDL-C, LDL-C,
smoking, exercise, caloric intake.
(TIF)
Figure S6 State-level Variation in Fully-Adjusted Fibrin-
ogen in the Women’s Health Study. Source: Women’s
Health Study Participants. Abbreviations: Q1: Lowest quintile of
inflammation; Q5: Highest quintile of inflammation. Fully-
adjusted models include: age, race/ethnicity, obese/overweight
status, systolic blood pressure, diabetes status, HDL-C, LDL-C,
smoking, exercise, caloric intake.
(TIF)
Figure S7 State-level Variation in Age-Adjusted Total
Cholesterol in the Women’s Health Study. Source:
Women’s Health Study Participants. Abbreviations: Q1: Lowest
quintile of risk; Q5: Highest quintile of risk.
(TIF)
Figure S8 State-level Variation in Age-Adjusted Total
Cholesterol:HDL Ratio in the Women’s Health Study.
Source: Women’s Health Study Participants. Abbreviations: Q1:
Lowest quintile of risk; Q5: Highest quintile of risk.
(TIF)
Figure S9 State-level Variation in Fully-Adjusted Total
Cholesterol in the Women’s Health Study. Source:
Women’s Health Study Participants. Abbreviations: Q1: Lowest
quintile of risk; Q5: Highest quintile of risk. Fully-adjusted
models include: age, race/ethnicity, obese/overweight status,
systolic blood pressure, diabetes status, smoking, exercise,
caloric intake.
(TIF)
Figure S10 State-level Variation in Fully-Adjusted Total
Cholesterol:HDL Ratio in the Women’s Health Study.
Source: Women’s Health Study Participants. Abbreviations: Q1:
Lowest quintile of risk; Q5: Highest quintile of risk. Fully-adjusted
models include: age, race/ethnicity, obese/overweight status,
systolic blood pressure, diabetes status, smoking, exercise, caloric
intake.
(TIF)
Figure S11 State-level Variation in Median Body Mass
Index in the Women’s Health Study. Source: Women’s
Health Study Participants. Model not adjusted for covariates.
(TIF)
Figure S12 State-level Variation in the Framingham
Point Score in the Women’s Health Study. Source:
Women’s Health Study Participants. Abbreviations: Q1: Lowest
quintile of risk; Q5: Highest quintile of risk. Model not adjusted for
covariates.
(TIF)
Figure S13 State-level Variation in the Reynolds Risk
Score in the Women’s Health Study. Source: Women’s
Health Study Participants. Abbreviations: Q1: Lowest quintile of
risk; Q5: Highest quintile of risk. Model not adjusted for
covariates.
(TIF)
Table S1 State-Level Median Values for Biomarkers of
Inflammation among Healthy Women in the Women’s
Health Study (N=26,029). *Estimates for District of Columbia
and Hawaii based on fewer than 50 participants.
(DOC)
Table S2 Fully-Adjusted Multi-Level Linear Regression
Models on log(hsCRP): Standardized b Coefficients, 95%
Confidence Intervals and Wald Tests (N=26,029). Source:
Women’s Health Study (WHS). Abbreviations: log(hsCRP) log
(High-Sensitivity C-Reactive Protein); NH (Non-Hispanic ethnicity);
HDL-C (high-density lipoprotein cholesterol); LDL-C (low-density
lipoprotein cholesterol); BMI (body mass index); ref. (reference
category). Standardized b coefficients estimated via multi-level
linear regression models adjusted for listed covariates. In our
primary analysis race ethnicity is modeled as non-White vs. NH-
White due to small numbers. In models with race as a categorical
variable, log(hsCRP) is lower among Asian/Pacific Islanders
compared to NH-Whites [Std b -0.26; 95% CI -0.35, -0.16; P
Value , 0.0001]. Hispanics tended to have higher log(hsCRP)
compared to NH-Whites [Std b 0.04; 95% CI -0.07, 0.16; P Value
0.48]. NH-Blacks tended to have higher log(hsCRP) compared to
NH-Whites [Std b 0.02; 95% CI -0.06, 0.11; P Value 0.61].
(DOC)
Table S3 Fully-Adjusted Multi-Level Linear Regression
Models on sICAM-1: Standardized b Coefficients, 95%
Confidence Intervals and Wald Tests (N=26,029). Source:
Women’s Health Study (WHS). Abbreviations: NH (Non-Hispanic
ethnicity); HDL-C (high-density lipoprotein cholesterol); LDL-C
(low-density lipoprotein cholesterol); BMI (body mass index); ref
(reference category). Standardized b coefficients estimated via
multi-level linear regression models adjusted for listed covariates.
In our primary analysis race ethnicity is modeled as non-White vs.
NH-White due to small numbers. In models with race as a
categorical variable, sICAM-1 is lower among Asian/Pacific Islanders
compared to NH-Whites [Std b -0.31; 95% CI -0.41, -0.22; P Value
, 0.0001]. Hispanics tended to have higher sICAM-1 compared to
NH-Whites [Std b 0.02; 95% CI -0.10, 0.14; P Value 0.72]. NH-
Blacks tended to have lower sICAM-1 values compared to NH-
Whites [Std b -0.67; 95% CI -0.76, 0.59; P Value , 0.0001].
(DOC)
Table S4 Fully-Adjusted Multi-Level Linear Regression
Models on Fibrinogen: Standardized b Coefficients, 95%
Confidence Intervals and Wald Tests (N=26,029). Source:
Women’s Health Study (WHS). Abbreviations: NH (Non-Hispanic
ethnicity); HDL-C (high-density lipoprotein cholesterol); LDL-C
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Standardized b coefficients estimated via multi-level linear
regression models adjusted for listed covariates. In our primary
analysis race ethnicity is modeled as non-White vs. NH-White due
to small numbers. In models with race as a categorical variable,
fibrinogen is higher among Asian/Pacific Islanders compared to
NH-White [Std b 0.07; 95% CI -0.03, 0.17; P Value 0.17].
Hispanics tended to have higher fibrinogen levels compared to
NH-Whites [Std b 0.09; 95% CI -0.03, 0.21; P Value 0.15]. NH-
Blacks tended to have higher fibrinogen levels compared to NH-
Whites [Std b 0.42; 95% CI 0.33, 0.50; P Value , 0.0001].
(DOC)
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